Introduction: Glioblastoma (GBM) is the most aggressive primary brain tumor, with high recurrence and limited treatment options. Oncolytic viruses (OVs) offer a promising therapeutic approach by selectively targeting tumor cells. Orthoflavivirus ilheusense (ILHV), a neurotropic flavivirus, may exploit cellular pathways like mTOR to induce oncolytic effects. Objectives: To evaluate ILHV’s oncolytic potential in GBM by analyzing viral replication and mTOR pathway gene expression. Methods: Vero E6 cells were used for ILHV stock preparation and titration (TCID50). The GBM cell line AHOL1 was infected with ILHV at MOI 1 for 72 hours. Viral RNA was extracted using the Biospin Total RNA Extraction II Bioflux® kit, and RT-qPCR was performed with GoTaq® kits to quantify mTORC1, mTORC2, Dicer, Drosha, and endogenous controls (RPL1, RP38). Data were analyzed using one-way ANOVA, Tukey’s test, and Pearson correlation in Jamovi 3.2. Results: ILHV induced cytopathic effects in AHOL1 cells, peaking at 72 hours. Viral replication was highest at 48 hours (p < 0.05). Drosha and Dicer expression decreased at 48 hours but increased at 72 hours, while mTORC1 and mTORC2 expression peaked at 72 hours (fold change >2, p < 0.01). A negative correlation was observed between viral load, mTORC2, and Dicer (r = -0.65, p < 0.05), while Drosha, mTORC1, and mTORC2 showed positive correlations (r > 0.70, p < 0.01). Conclusion: ILHV exhibits significant oncolytic activity against GBM, modulating mTOR signaling and miRNA biogenesis pathways, similar to other flaviviruses like Zika virus but with potentially unique neurotropic advantages. As an in vitro study, its translational potential requires validation in vivo. Future studies in animal models are essential to confirm ILHV’s efficacy and safety for GBM therapy.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
